3M signs licensing agreement with Spirig Pharma
Spirig will use 3M’s IRM molecule in treatment for sun-damaged skin
3M Drug Delivery Systems has licensed one of its immune response modifier (IRM) molecules to Spirig Pharma, a Swiss manufacturer of dermatological and dermocosmetic products, extending its international reach.
Spirig will use the molecule in the development of a treatment for sun-damaged skin. Spirig is known internationally for brands such as Daylong actinica, a medical device for the prevention of certain forms of non-melanoma skin cancer, and Excipial moisturiser.
3M Drug Delivery Systems develops IRMs for cancer, asthma and allergy treatment, as well as compounds for vaccine adjuvants.
The company expects that the deal with Spirig, which has a number of subsidiaries across the EU, will expand its international reach.
Mark Tomai, vaccine business development director for 3M Drug Delivery Systems, said: ‘The molecule offers potential for treating patients who suffer from a variety of dermatologic conditions.’
